The FDA has approved Alcon’s Patanase (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. Patanase will be available in May, Alcon said.
GlaxoSmithKline and Pozen announced FDA approval of Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet combines a GSK-developed triptan designed to target migraines, with an anti-inflammatory pain reliever in single tablet form.
